Crisil assigns ESG rating of 61 (Strong) to Aarti Drugs for FY26

Business Updates View source PDF Explain this filing

AARTIDRUGS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹418.00

prior close

₹415.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-1.6% vs market

Pharmaceuticals peers, median of 168sector-0.2%-1.2% vs sector

On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.8

15m

-0.5

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3+0.3-1.6-0.2-1.2

Next day

-1.5+1.1-2.6-0.2-1.3

-2.0+1.3-3.3-0.4-1.6

-4.2+2.0-6.3-0.7-3.5

-5.3+0.3-5.6-1.1-4.1

-5.3+1.1-6.3-0.8-4.4

-7.4-3.2-4.2-4.1-3.3

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Drugs has been assigned a Crisil ESG rating of 61, classified as Strong, based on publicly available data for FY 2025-26. The rating was prepared independently by Crisil ESG Ratings, a SEBI-registered Category-1 provider, without the company engaging them. The disclosure is filed under SEBI LODR Regulation 30.

Likely market impact

Positive ESG recognition; may attract ESG-focused investors but limited direct impact on short-term share price.